Frequency of Facial Angiofibromas in Japanese Patients with Multiple Endocrine Neoplasia Type 1

The high frequency of cutaneous manifestations in patients with multiple endocrine neoplasia type 1 (MEN 1) has recently been reported. Since prevalence of some cutaneous diseases varies among different ethnic groups, we examined the frequency of facial angiofibromas in Japanese patients with famili...

Full description

Saved in:
Bibliographic Details
Published in:Endocrine Journal 2000, Vol.47(5), pp.569-573
Main Authors: SAKURAI, AKIHIRO, MATSUMOTO, KAZUHIKO, IKEO, YASUTO, NISHIO, SHIN-ICHI, KAKIZAWA, TOMOKO, ARAKURA, FUYUKO, ISHIHARA, YASUSHI, SAIDA, TOSHIAKI, HASHIZUME, KIYOSHI
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Angiofibroma - diagnosis
Angiofibroma - ethnology
Angiofibroma - genetics
Asian Continental Ancestry Group - genetics
Face
Female
Humans
Japan - epidemiology
Male
MENI
Middle Aged
Multiple Endocrine Neoplasia Type 1 - diagnosis
Multiple Endocrine Neoplasia Type 1 - genetics
Mutation
Neoplasm Proteins - genetics
Proto-Oncogene Proteins
Skin Neoplasms - ethnology
Skin Neoplasms - genetics
Skin tumor
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The high frequency of cutaneous manifestations in patients with multiple endocrine neoplasia type 1 (MEN 1) has recently been reported. Since prevalence of some cutaneous diseases varies among different ethnic groups, we examined the frequency of facial angiofibromas in Japanese patients with familial MEN 1. Among 27 patients with germline MENI gene mutation and one asymptomatic gene carrier, angiofibromas were identified in 43% (12/28) of the subjects. This frequency was significantly lower than that of Caucasian patients, but nonetheless almost equaled those of pituitary tumors and pancreas endocrine tumors. Angiofibromas should be considered as one of major manifestations in MEN 1 regardless of patients' ethnic origin, and clinicians should pay careful attention to the cutaneous lesions in patients with endocrine tumors.
ISSN:0918-8959
1348-4540
DOI:10.1507/endocrj.47.569